Stereotactic Radiosurgery - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The stereotactic radiosurgery market size is expected to increase from USD 73.03 billion in 2025 to USD 77.22 billion in 2026 and reach USD 104.04 billion by 2031, growing at a CAGR of 6.14% over 2026-2031. This report is Segmented by Product Type (Stereotactic Radiosurgery Systems, Others), Technology (Gamma Knife Technology, Others), Application (Brain Tumors, Arteriovenous Malformations, Others), End-User (Hospitals, Ambulatory Surgical Centers, Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Stereotactic Radiosurgery Market Trends and Insights

Rising Burden of Brain Metastases and Functional Neurological Disorders

The stereotactic radiosurgery market is benefiting from a broader patient pool than incidence counts alone suggest, because longer survival in breast, lung, and melanoma care is creating more cases with isolated or limited central nervous system recurrence. Those patients often fit stereotactic treatment better than whole-brain radiation or open surgery, which supports repeat procedure demand over time. This means the stereotactic radiosurgery market is seeing volume growth that is not fully visible through hardware installation counts alone. The neurological side of demand also widened when Elekta received U.S. FDA 510 (k) clearance in July 2025 for refractory, drug-resistant mesial temporal lobe epilepsy in adults, which added a durable non-oncology use case to the installed base. That clearance matters because it opens a patient population that had been more dependent on invasive resection. It also gives the stereotactic radiosurgery market a recurring demand layer that is less exposed to oncology treatment cycles.

Shift Toward Non-Invasive, Outpatient Neuro-Oncology Care

The stereotactic radiosurgery market is moving toward same-day outpatient treatment as mask-based and frameless approaches replace older invasive workflows in many intracranial cases. This shift helps providers reduce admission burden while preserving local control, which makes radiosurgery easier to position against surgery in selected patients. The stereotactic radiosurgery market is also supported by new installations that make outpatient delivery more practical. Health Sciences Center Winnipeg deployed Elekta Esprit in January 2026 with integrated CT imaging, which removed the same-day MRI requirement and enabled fractionated treatment for larger tumors that had been harder to manage in a single session. Accuray widened access in Austria in May 2025 through the country’s first CyberKnife facility, and it also supported first patient treatments in Melbourne in October 2025 through its work with Icon Group, which signaled a broader East Coast expansion path in Australia. These changes help the stereotactic radiosurgery market fit ambulatory care models that value short sessions, predictable throughput, and lower dependence on inpatient infrastructure.

High Capital Cost of Vaults, Shielding, and Platform Installation

The stereotactic radiosurgery market still faces a structural access problem because total project cost extends well beyond the headline price of the treatment platform. Shielded bunker construction can add USD 1 million to USD 3 million per installation, which is a major barrier for community oncology centers and stand-alone outpatient settings. This keeps much of the stereotactic radiosurgery market concentrated in better-funded institutions that can absorb both equipment and facility costs. Even so, the stereotactic radiosurgery market still runs on a global installed base where conventional infrastructure assumptions remain common. That means cost pressure continues to slow first-time adoption in lower-resource regions even as newer architectures gain visibility.

Other drivers and restraints analyzed in the detailed report include:

• AI-Enabled Treatment Planning and Workflow Automation
• Reimbursement Support for High-Precision Radiation in Mature Markets
• Cobalt-60 Supply Dependence for Gamma Knife Installations

Segment Analysis

Stereotactic radiosurgery systems held 51.24% of the stereotactic radiosurgery market share in 2025, which kept hardware at the center of revenue generation even as the business mix started to shift. The largest share still reflects the capital intensity of treatment platforms and the replacement cycle now underway at major academic centers. The stereotactic radiosurgery market is seeing this most clearly in Gamma Knife upgrades, where newer systems are replacing aging units rather than opening entirely new accounts.

Treatment planning and simulation software is expected to be the fastest-growing product type at 6.36% CAGR through 2031, and that is changing how revenue is captured over the life of an installed system. Software is moving procurement toward subscriptions, upgrades, and service contracts that continue after the initial hardware sale. The stereotactic radiosurgery industry is therefore seeing value move into workflow intelligence, contouring, optimization, and treatment planning support rather than remaining concentrated in the machine alone. Services and supporting technologies still matter, but their role increasingly depends on the size and quality of the installed base that software is helping to monetize more effectively.

Gamma knife technology accounted for 41.27% of technology-segment revenue in 2025, which shows how strongly long clinical use, intracranial specialization, and installed-base depth still shape buying patterns. That leadership remains tied to academic center demand and to recurring replacement and source-related needs in mature markets. The stereotactic radiosurgery market still treats Gamma Knife as the benchmark for intracranial precision in many hospital settings. At the same time, the stereotactic radiosurgery market is giving more weight to technologies that ease infrastructure demands and widen placement opportunities beyond large referral centers.

Robotic radiosurgery technology is projected to grow at 6.64% CAGR through 2031, which makes it the fastest-advancing technology segment in the stereotactic radiosurgery market. Growth is tied to cobalt-free and in some cases vault-light or vault-free positioning, which lowers the barrier for outpatient centers and specialty clinics. LINAC-based SRS remains the second-largest technology category because large radiation oncology departments can use shared infrastructure across conventional radiotherapy and radiosurgery. The stereotactic radiosurgery industry is therefore moving toward a technology comparison that weighs workflow, infrastructure, and resilience just as heavily as dose delivery performance.

Complete Report Scope:

• By Product Type
  • Stereotactic Radiosurgery Systems
  • Treatment Planning and Simulation Software
  • Supporting Technologies
  • Services
• By Technology
  • Gamma Knife Technology
  • LINAC-Based SRS Technology
  • Robotic Radiosurgery Technology
  • Proton Beam Radiosurgery Technology
  • Image-Guided Radiosurgery Technology
  • AI-Assisted Radiosurgery Technology
• By Application
  • Brain Tumors
  • Arteriovenous Malformations
  • Trigeminal Neuralgia
  • Spinal Tumors and Lesions
  • Functional Disorders
• By End-User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics/Centers
  • Research and Academic Institutes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 44.27% of the stereotactic radiosurgery market share in 2025, which kept it as the largest regional contributor to current revenue. The United States supports that position through a dense concentration of academic cancer centers, ongoing replacement demand, and a CMS reimbursement structure that explicitly covers gamma knife, LINAC-based, and robotic stereotactic radiation therapy across defined intracranial indications. Payment clarity matters because it reduces hesitation around both utilization and capital planning in established programs. The stereotactic radiosurgery market in Canada also remains active, and Health Sciences Centre Winnipeg unveiled a USD 3.2 million Elekta Esprit system in January 2026 with integrated CT imaging and fractionation support for larger tumors. Mexico remains a smaller but advancing part of the regional stereotactic radiosurgery market, supported by private hospital expansion and medical tourism demand for advanced oncology procedures.

Europe ranks second in the stereotactic radiosurgery market, with Germany, the United Kingdom, France, Italy, and Spain accounting for the largest regional demand base. National cancer strategies and public funding support are widening access beyond top referral hospitals, which is helping secondary centers participate in precision radiotherapy adoption. France also strengthened its position as an early adopter with the late 2025 installation of the Varian Halcyon 5.0 platform with integrated real-time motion management at Institut du Cancer Avignon-Provence, while Italy continued its Esprit replacement cycle through active Gamma Knife upgrades.

Asia-Pacific is projected to post the fastest 8.33% CAGR in the stereotactic radiosurgery market size through 2031, which reflects a wider installation runway and rising investment in high-precision oncology infrastructure. China is a major part of that story after Accuray received dual NMPA approvals in January 2025, and the company stated that China may need around 2,000 radiation therapy systems over the next 5 years. India is also expanding its advanced treatment base, with IBA’s 2025 agreements with AIG Hospitals and Apollo Hospitals expected to add compact proton capacity and lift the country’s proton center count over time. Australia showed momentum in outpatient radiosurgery when Accuray and Icon Group supported first patient treatments in Melbourne in October 2025, while the Middle East, Africa, and South America remain smaller but active investment regions led by public-private oncology capacity additions.

List of Companies Covered in this Report:

• Accuray
• Brain Lab
• BRAINLAB AG
• CIVCO Radiotherapy
• Elekta
• FHC, Inc.
• GE HealthCare Technologies Inc.
• Hitachi
• IBA, Ion Beam Applications S.A.
• Mevion Medical Systems, Inc.
• Mitsubishi Electric Corporation
• Monteris Medical Corporation
• Neusoft
• Panacea Medical Technologies
• Philips N.V.
• Shinva Medical Instrument Co., Ltd.
• Siemens Healthineers
• Varian Medical Systems, Inc.
• ViewRay, Inc.
• ZAP Surgical Systems, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support